{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:44:01Z","timestamp":1778604241423,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.eimc.2016.09.013","type":"journal-article","created":{"date-parts":[[2016,11,22]],"date-time":"2016-11-22T19:30:34Z","timestamp":1479843034000},"page":"499-504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Activity of ceftazidime\u2013avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance"],"prefix":"10.1016","volume":"35","author":[{"given":"Inmaculada","family":"L\u00f3pez-Hern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noem\u00ed","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Fern\u00e1ndez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Zamorano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Carmen","family":"Conejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Mart\u00ednez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferr\u00e1n","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2016.09.013_bib0110","series-title":"State of the World's antibiotics, 2015","author":"Center for Disease Dynamics, Economics & Policy","year":"2015"},{"key":"10.1016\/j.eimc.2016.09.013_bib0115","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1128\/AAC.28.2.302","article-title":"Evolution of plasmid-coded resistance to broad-spectrum cephalosporins","volume":"28","author":"Kliebe","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2016.09.013_bib0120","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.idc.2016.02.003","article-title":"The continuing plague of extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae Infections","volume":"30","author":"Adler","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.eimc.2016.09.013_bib0125","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/CMR.00036-08","article-title":"AmpC beta-lactamases","volume":"22","author":"Jacoby","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.eimc.2016.09.013_bib0130","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1128\/CMR.00043-12","article-title":"Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance","volume":"25","author":"Fern\u00e1ndez","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.eimc.2016.09.013_bib0135","unstructured":"US Food and Drug Administration. 2015. Avycaz (ceftazidime\u2013avibactam) package insert. NDA 206494. Product labeling: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206494s000lbl.pdf."},{"key":"10.1016\/j.eimc.2016.09.013_bib0140","unstructured":"Astra Zeneca. A phase III, randomized, multicentre, double-blind, double-dummy, parallel-group comparative study to determine the efficacy, safety and tolerability of ceftazidime\u2013avibactam versus meropenem in the treatment of nosocomial pneumonia including ventilator-associated pneumonia in hospitalized adults. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2013\u20132016. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01808092 NLM Identifier: NCT01808092."},{"key":"10.1016\/j.eimc.2016.09.013_bib0145","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second generation \u03b2-lactam\/\u03b2-lactamase combinations","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2016.09.013_bib0150","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ijantimicag.2015.12.021","article-title":"New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance","volume":"47","author":"Syue","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.eimc.2016.09.013_bib0155","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1128\/JCM.02147-09","article-title":"Diversity of Escherichia coli strains producing extended-spectrum beta-lactamases in Spain: second nationwide study","volume":"48","author":"D\u00edaz","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.eimc.2016.09.013_bib0160","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1128\/JCM.02514-10","article-title":"Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases in Spain: microbiological and clinical features","volume":"49","author":"Ruiz de Alegr\u00eda","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.eimc.2016.09.013_bib0165","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.diagmicrobio.2008.01.023","article-title":"Effect of porin loss on the activity of tigecycline against Klebsiella pneumoniae producing extended-spectrum beta-lactamases or plasmid-mediated AmpC-type beta-lactamases","volume":"61","author":"Conejo","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.eimc.2016.09.013_bib0170","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10096-012-1737-0","article-title":"Prevalence and molecular epidemiology of acquired AmpC \u03b2-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain","volume":"32","author":"Mir\u00f3","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.eimc.2016.09.013_bib0175","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.1128\/AAC.00818-13","article-title":"Characterization of the new AmpC \u03b2-lactamase FOX-8 reveals a single mutation, Phe313Leu, located in the R2 loop that affects ceftazidime hydrolysis","volume":"57","author":"P\u00e9rez-Llarena","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2016.09.013_bib0180","unstructured":"Clinical and Laboratory Standards Institute. 2015. M100-S25. Performance standards for antimicrobial susceptibility testing, 25th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"10.1016\/j.eimc.2016.09.013_bib0185","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2016. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0, valid from 2016-01-01. European Committee on antimicrobial susceptibility Testing, Vaxjo, Sweden."},{"key":"10.1016\/j.eimc.2016.09.013_bib0190","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1128\/AAC.02286-15","article-title":"Activity of ceftazidime\u2013avibactam against extended-spectrum- and AmpC \u03b2-lactamase-producing Enterobacteriaceae collected in the INFORM Global Surveillance Study from 2012 to 2014","volume":"60","author":"Karlowsky","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2016.09.013_bib0195","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1128\/AAC.01585-15","article-title":"Role of the outer membrane and porins in susceptibility of \u03b2-Lactamase-producing Enterobacteriaceae to ceftazidime\u2013avibactam","volume":"60","author":"Pages","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2016.09.013_bib0200","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1128\/AAC.01275-10","article-title":"Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence","volume":"55","author":"Tsai","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2016.09.013_bib0205","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1128\/AAC.01559-15","article-title":"Molecular characterization of carbapenem-non susceptible enterobacterial isolates collected during a prospective interregional survey in France and susceptibility to the novel ceftazidime\u2013avibactam and aztreonam\u2013avibactam combinations","volume":"60","author":"Dupont","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2016.09.013_bib0210","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1128\/AAC.03057-14","article-title":"Avibactam and class C \u03b2-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance","volume":"58","author":"Lahiri","year":"2014","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X16303226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X16303226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T13:50:53Z","timestamp":1536241853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X16303226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0213005X16303226"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2016.09.013","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of ceftazidime\u2013avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance","name":"articletitle","label":"Article Title"},{"value":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2016.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.","name":"copyright","label":"Copyright"}]}}